HCM Conference - Agenda

Friday, October 16, 2009

Diagnosis/Structure/Etiology and Disease Expression
7:30 a.m.	Registration, continental breakfast, exhibits
8:30	Welcome: The Next 50 Years of HCM Barry J. Maron, MD — Minneapolis Heart Institute Foundation
8:35 a.m.	Basic principles: Definition, names, phenotypic expression, prevalence, pathophysiology and differential diagnosis Barry J. Maron, MD — Minneapolis Heart Institute Foundation
9:10	The first 20 years of genomics: Clinical role of genetic testing, animal models, and phenocopies Christine E. Seidman, MD — Brigham and Women’s Hospital
9:50	Genetic testing for the diagnosis of HCM: How to interpret the reports Heidi L. Rehm, PhD. — Harvard Medical School
10:20	Break
10:45	Preclinical HCM: Identification and management considerations Carolyn Y. Ho, MD — Brigham and Women’s Hospital
11:20	HCM and spectrum of related cardiomyopathies in infancy and childhood, including Fabry, Noonan and other HCM phenocopies Jeffrey A. Towbin, MD — Cincinnati Children’s Hospital
11:55	New diagnostic imaging modalities: What we have learned from CMR about the HCM phenotype…myocardium and mitral valve…beyond echocardiography Martin S. Maron, MD — Tufts Medical Center
12:40 p.m.	Luncheon Panel: The Three Masters E. Douglas Wigle, MD — Toronto General Hospital Pravin M. Shah, MD — Hoag Heart & Vascular Institute Eugene Braunwald, MD — Brigham and Women’s Hospital
Clinical Course and Prognosis: Heart failure
1:35 p.m.	Overview of natural history and clinical course Barry J. Maron, MD — Minneapolis Heart Institute Foundation
2:10	Genes and prognosis: Can mutations predict the future? Michael J. Ackerman, MD — Mayo Clinic
2:45	The left atrium and atrial fibrillation Iacopo Olivotto, MD — Careggi University Hospital
3:20	The spectrum of progressive heart failure in HCM: Clinical-pathologic correlations Gaetano Thiene, MD — University of Padua
3:55	Break
4:20	Clinical evidence for myocardial ischemia, coronary flow reserve, and mechanisms of heart failure Franco Cecchi, MD — Careggi University Hospital
4:55	HCM as a predominantly obstructive disease: The historical context of LV outflow obstruction, and full-circle from IHSS to obstructive HCM Eugene Braunwald, MD – Brigham and Women’s Hospital
5:30	Clinical spectrum of the “end-stage” Iacopo Olivotto, MD — Careggi University Hospital
6:05	Adjournment
7:00	Private dinner cruise on the Mississippi River aboard the Betsey Northrup, departing from Harriet Island in downtown St. Paul Padelford Mississippi Riverboat Tour The dinner cruise is a unique social activity created to encourage interaction between faculty and Summit registrants. We encourage everyone to participate! The "Mighty Mississippi" is a huge part of the rich cultural and industrial history of the Minneapolis-St. Paul area. This private charter cruise will depart near the Science Museum of Minnesota and take you through the heart of the Great River National Park.
10:00	Cruise returns to dock

Saturday, October 17, 2009

Identification of the High-Risk Patient
7:30 a.m.	Continental breakfast and exhibits
8:20 a.m.	Brief introduction to risk stratification strategies and selection of high risk patients in HCM Barry J. Maron, MD — Minneapolis Heart Institute Foundation
8:30	Three Primary Prevention Risk Markers: Prognostic significance of syncope, LVH and the ambulatory Holter. Sudden death risk without risk factors? Paolo Spirito, MD — Ente Ospedaliero Ospedali Galleria
9:00	Two Primary Prevention Risk Markers: Prognostic significance of family history of sudden death...and blood pressure response to exercise Steve Ommen, MD — Mayo Clinic
9:40	New potential risk markers. Status of CMR post-contrast delayed enhancement and LV mass Martin S. Maron, MD — Tufts Medical Center
10:15	Break
10:40	Prevention of sudden death with the implantable cardioverter-defibrillator Barry J. Maron, MD — Minneapolis Heart Institute Foundation
11:20	An electrophysiologist’s perspective on mechanisms and decision-making for sudden death prevention N.A. Mark Estes, III, MD — Tufts Medical Center
12:00 p.m.	The defibrillator industry and HCM: The good and the bad: progress in device quality with optimism for the future Robert G. Hauser, MD — Minneapolis Heart Institute Foundation
12:35	Luncheon. The HCMA after one decade: Evolution of HCM centers in the U.S. Lisa Salberg — Hypertrophic Cardiomyopathy Association
HCM Around the World
1:45 p.m.	Cardiovascular pathology is “alive and well” in Italy: Evidence for the unstable myocardial substrate and significance (or lack thereof) of myocardial bridging as a risk factor Cristina Basso, MD — University of Padua
2:20	From “Down Under”: Insights on establishing a national HCM center in a “small” country Christopher Semsarian, MD, PhD — Royal Prince Alfred Hospital
2:55	Athlete’s heart and its distinction from HCM: Consensus guidelines for eligibility/disqualification from sports competition to reduce risk Antonio Pelliccia, MD — Italian National Olympic Committee
3:30	Break
4:00	Debate: What is the most effective strategy for preparticipation screening to detect cardiovascular abnormalities in trained athletes? Point: The Italian model saves lives and is best... even here Domenico Corrado, MD – University of Padua …for the Italians Counterpoint: The U.S. Perspective Barry J. Maron, MD - Minneapolis Heart Institute Foundation ….for the American Heart Association
4:45	Prevalence and clinical/genetic spectrum of HCM in China Rutai Hui, MD — Fu Wai Hospital and Cardiovascular Institute (Beijing)
5:20	Adjournment

Sunday, October 18, 2009

Strategies for Treatment of Heart Failure
7:30 a.m.	Continental breakfast and exhibits
8:30 a.m.	The spectrum of pharmacologic treatment Mark V. Sherrid, MD — Roosevelt-St. Luke’s Hospital
9:00	Techniques, indications and results of surgical septal myectomy: The historic gold standard Joseph A. Dearani, MD — Mayo Clinic
9:40	The Toronto surgical myectomy experience: Determinants of success and prognosis Anna Woo, MD and E. Douglas Wigle, MD —- Toronto General Hospital
10:15	Does surgical septal reduction prolong life and is there a case for earlier intervention? Steve R. Ommen, MD — Mayo Clinic
10:50	Alternatives to surgery: A decade of alcohol ablation…where do we stand now? Rick Nishimura, MD — Mayo Clinic
11:25	Surgical myectomy vs. alcohol septal ablation: What about a randomized trial? Role of the mitral apparatus Harry M. Lever, MD — Cleveland Clinic Foundation
12:00 p.m.	Closing: The Next 50 Years Barry J. Maron, MD — Minneapolis Heart Institute Foundation
12:10	Adjournment